High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma (Q24200296)

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

The role of surgery in stage IV neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Metastatic neuroblastoma in children older than one year old at diagnosis. Treatment with intensive chemo-radiotherapy and autologous bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

[Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent children's cancer group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Neuroblastoma in Turkish children: experience of a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Micrometastases in neuroblastoma: are they clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

A proposed staging for children with neuroblastoma.Children's cancer study group A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Neuroblastoma: evolving therapies for a disease with many faces

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Statistical considerations in the intent-to-treat principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

The biologic basis for neuroblastoma heterogeneity and risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

"Megatherapy" for advanced neuroblastoma--rationale and role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Detection and treatment of minimal residual disease in high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Advances in the diagnosis and treatment of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Assessment of reporting quality of conference abstracts in sports injury prevention according to CONSORT and STROBE criteria and their subsequent publication rate as full papers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

High dose chemotherapy and autologous stem cell rescue for children with high risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

The treatment of advanced neuroblastoma. Results of the spanish neuroblastoma study group (SNSG) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

Long-term cause-specific mortality among survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma withMYCN amplification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Analysis of clinical trials by treatment actually received: is it really an option?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006301.PUB3

7 January 2021

10.1002/14651858.CD006301.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23970444

1 reference

Consolidated OpenCitations Corpus – April 2017